Biogen Inc. ((BIIB)), Biogen ((CC:HTER)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Biogen Inc. (BIIB) is conducting a Phase 3 long-term extension study titled ‘A Multicenter, Randomized, Dose-Blind, Phase 3 Long-Term Extension Study to Evaluate Continuous Safety and Efficacy of Litifilimab (BIIB059) in Adult Participants With Active Systemic Lupus Erythematosus.’ The study aims to assess the long-term safety and efficacy of litifilimab in adults with active systemic lupus erythematosus (SLE), focusing on adverse events, symptom control, and quality of life.
The study tests litifilimab, an experimental drug administered via subcutaneous injections every four weeks, intended to improve symptoms in SLE patients. Participants continue their standard care medications alongside the study drug.
This randomized, parallel-assignment study uses a quadruple masking approach, meaning neither participants nor care providers, investigators, or outcomes assessors know the treatment allocations. The primary goal is treatment-focused, aiming to ensure the drug’s safety and effectiveness over an extended period.
The study began on June 10, 2022, with an estimated completion date in August 2025. These dates are crucial as they guide investors on the timeline for potential market entry and regulatory milestones.
This study update could influence Biogen’s stock performance by bolstering investor confidence if results show litifilimab’s safety and efficacy. Success in this study may position Biogen favorably against competitors in the SLE treatment market, potentially impacting investor sentiment positively.
The study is ongoing, with further details available on the ClinicalTrials portal.